Mitsubishi UFJ Asset Management
RPRX icon

Mitsubishi UFJ Asset Management’s Royalty Pharma RPRX Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.5M Buy
472,798
+30,020
+7% +$1.56M 0.01% 501
2026
Q1 		$21.2M Buy
442,778
+29,703
+7% +$1.3M 0.01% 509
2025
Q4 		$16.1M Buy
413,075
+56,043
+16% +$2.14M 0.01% 538
2025
Q3 		$12.6M Buy
357,032
+44,289
+14% +$1.6M 0.01% 560
2025
Q2 		$11.3M Buy
312,743
+1,154
+0.4% +$38.2K 0.01% 564
2025
Q1 		$9.7M Buy
311,589
+55,400
+22% +$1.76M 0.01% 579
2024
Q4 		$6.62M Buy
256,189
+835
+0.3% +$22.1K 0.01% 621
2024
Q3 		$7.22M Buy
255,354
+38,919
+18% +$1.08M 0.01% 600
2024
Q2 		$5.71M Hold
216,435
– – 0.01% 623
2024
Q1 		$6.57M Buy
216,435
+29,672
+16% +$875K 0.01% 590
2023
Q4 		$5.18M Buy
186,763
+1,223
+0.7% +$33.6K 0.01% 598
2023
Q3 		$5.04M Buy
185,540
+23,110
+14% +$686K 0.01% 589
2023
Q2 		$4.99M Buy
162,430
+43,118
+36% +$1.46M 0.01% 588
2023
Q1 		$4.3M Buy
119,312
+12,128
+11% +$450K 0.01% 597
2022
Q4 		$4.22M Buy
107,184
+8,800
+9% +$367K 0.01% 583
2022
Q3 		$3.95M Buy
98,384
+8,100
+9% +$346K 0.01% 586
2022
Q2 		$3.8M Buy
90,284
+8,700
+11% +$357K 0.02% 591
2022
Q1 		$3.18M Sell
81,584
-1,452
-2% -$57K 0.01% 648
2021
Q4 		$3.26M Buy
83,036
+38,800
+88% +$1.51M 0.01% 669
2021
Q3 		$1.6M Buy
44,236
+7,900
+22% +$307K 0.01% 769
2021
Q2 		$1.49M Sell
36,336
-277
-0.8% -$11.8K 0.01% 792
2021
Q1 		$1.6M Buy
36,613
+14,949
+69% +$709K 0.01% 738
2020
Q4 		$1.08M Buy
+21,664
New +$919K 0.01% 749

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mitsubishi UFJ Asset Management's RPRX Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management increased its Royalty Pharma (RPRX) stake by 6.8% in Q2 2026, buying an estimated $1.56M and bringing the position to 472,798 shares worth $26.5M. The position accounts for 0.01% of the portfolio, ranked #501.

Mitsubishi UFJ Asset Management first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 472,798 shares of Royalty Pharma worth $26.5M as of Q2 2026.
  • Mitsubishi UFJ Asset Management bought 30,020 Royalty Pharma shares in Q2 2026, an estimated $1.56M.
  • Royalty Pharma made up 0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #501 holding.
  • Mitsubishi UFJ Asset Management first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.